CytoAgents, Quotient Sciences to take COVID-19 drug candidate GP1681 into human trials
US biotech company CytoAgents has joined forces with CDMO and CRO services provider Quotient Sciences to accelerate the development of its COVID-19 drug candidate GP1681 into ... Read More
Quotient Sciences opens new $15m facility in Garnet Valley to boost drug development capabilities
Quotient Sciences, a UK-based drug development services provider, has inaugurated a new early phase formulation and manufacturing plant in Garnet Valley, Pennsylvania. The facility, spanning ... Read More